Blueshift Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Blueshift Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,226	Closed	-$406K	–	542
2025 Q1	$406K	Buy	+1,226	New	+$403K	0.16%	203
2024 Q4	–	Sell	-1,852	Closed	-$393K	–	456
2024 Q3	$393K	Buy	+1,852	New	+$474K	0.1%	231
2023 Q3	–	Sell	-3,139	Closed	-$725K	–	369
2023 Q2	$725K	Buy	3,139 +808	+35%	+$219K	0.28%	90
2023 Q1	$565K	Buy	+2,331	New	+$635K	0.24%	123
2022 Q2	–	Sell	-4,348	Closed	-$427K	–	885
2022 Q1	$427K	Buy	+4,348	New	+$367K	0.04%	490

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Blueshift Asset Management's MDGL Position: Q2 2025 in Review

Blueshift Asset Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 1,226 shares — an estimated $406K sold.

Blueshift Asset Management first reported a position in MDGL in Q1 2022 and held it in 5 quarters. The position peaked at $725K in Q2 2023. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

Blueshift Asset Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Blueshift Asset Management sold 1,226 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $406K.
Blueshift Asset Management first reported a position in Madrigal Pharmaceuticals in Q1 2022 and held it in 5 quarters.
Blueshift Asset Management's Madrigal Pharmaceuticals position peaked at $725K in Q2 2023.
305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on Blueshift Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.